메틀러톨레도(MTD) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

MTD

Mettler-Toledo International Inc

7월 27일 2:47 PM ET (한국 7/28 03:47)

$1327.18

-4.69 ▼ -0.35%

메틀러톨레도(MTD) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$26.8B

미드캡

P/E

31.1

적정 수준

배당수익률

없음

52주 위치

61%

저점 +30% · 고점 -13%

애널리스트

매수

C+

Fundamental health

vs. 성장주 대형주

수익성

Top 8%

성장

Top 74%

밸류에이션

Top 47%

재무 안정

Top 70%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 5년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 31원. Over the past 5년, it usually traded around 35원. On the cheaper side versus its own history.

Pricy doesn't mean bad — it means expectations are already baked in.

Index ⓘ	S&P 500	P/E ⓘ	31.13	EPS (ttm) ⓘ	42.64	Insider Own ⓘ	0.73%	Shs Outstand ⓘ	20.2M	Perf Week ⓘ	1.31%
Market Cap ⓘ	26.82B	Forward P/E ⓘ	25.96	EPS next Y ⓘ	9.55%	Insider Trans ⓘ	-0.54%	Shs Float ⓘ	20.1M	Perf Month ⓘ	10.31%
Enterprise Value ⓘ	28.99B	PEG ⓘ	2.6	EPS next Q ⓘ	10.79	Inst Own ⓘ	103.12%	Short Float ⓘ	3.67%	Perf Quarter ⓘ	4.97%
Income ⓘ	0.88B	P/S ⓘ	6.56	EPS this Y ⓘ	9.23%	Inst Trans ⓘ	-0.66%	Short Ratio ⓘ	3.54	Perf Half Y ⓘ	-7.71%
Sales ⓘ	4.09B	P/B ⓘ	-	EPS next 5Y ⓘ	10%	ROA ⓘ	25.35%	Short Interest ⓘ	0.74M	Perf YTD ⓘ	-4.81%
Book/sh ⓘ	-2.07	P/C ⓘ	442.78	EPS past 3/5Y ⓘ	3.07% 11.04%	ROE ⓘ	-	52W High ⓘ	-12.98% ($1525.17)	Perf Year ⓘ	5.27%
Cash/sh ⓘ	3	P/FCF ⓘ	33.78	Sales past 3/5Y ⓘ	0.9% 5.47%	ROIC ⓘ	41.28%	52W Low ⓘ	29.73% ($1023.05)	Perf 3Y ⓘ	-2.56%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	23.11	EPS Y/Y TTM ⓘ	6.19%	Gross Margin ⓘ	57.31%	Volatility(W/M) ⓘ	3.42% 2.82%	Perf 5Y ⓘ	-10.15%
Dividend TTM ⓘ	-	EV/Sales ⓘ	7.09	Sales Y/Y TTM ⓘ	6.78%	Oper. Margin ⓘ	27.52%	ATR (14) ⓘ	37.52	Perf 10Y ⓘ	242.87%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	0.84	EPS Q/Q ⓘ	6.68%	Profit Margin ⓘ	21.4%	RSI (14) ⓘ	60.92	Recom ⓘ	2.25
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.2	Sales Q/Q ⓘ	7.17%	SMA20 ⓘ	2.38% ($1296.33)	Beta ⓘ	1.23	Target Price ⓘ	$1348.91
Payout ⓘ	-	Debt/Eq ⓘ	-	Earnings ⓘ	2026/7/30	SMA50 ⓘ	10.82% ($1197.6)	Rel Volume ⓘ	0.9	Prev Close ⓘ	$1331.87
Employees ⓘ	18100	LT Debt/Eq ⓘ	-	EPS/Sales Surpr. ⓘ	2.27% 0.42%	SMA200 ⓘ	0.81% ($1316.52)	Avg Volume(3M) ⓘ	0.21M	Price ⓘ	$1327.18
IPO ⓘ	1997/11/14	Option/Short ⓘ	Yes/Yes			Trades ⓘ	7098	Volume ⓘ	187,718	Change ⓘ	-0.35%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $947M (YoY +7%) · 순이익 $169M (YoY +4%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Mettler-Toledo International Inc (MTD) Investment Analysis

What kind of company is Mettler-Toledo International Inc?

메틀러톨레도(MTD) 성장주

Healthcare · Diagnostics & Research

#506 by Market Cap — Mid-Cap

🔬 Mettler-Toledo (MTD) is a global leader in designing and manufacturing precision laboratory balances, industrial measurement solutions, and scales for food retail distribution. The company is an equipment-solution provider that generates stable margin structure and long-term cash flow based on strong brand trust across various regulated industries such as pharmaceuticals, chemicals, and food.

Learn more about Mettler-Toledo International Inc →

Market Cap

$26.8B

Approx. KRW 36.7 trillion

⚖️ 9% of Samsung Electronics

Market Cap Rank506

Employees18,100people

IPO1997/11/14

Current Price$1327.18 ≈ 1,818,237원

📌 S&P 500 · NYSE · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-3

7월 30일 (목) · 장 마감 후

예상 EPS $10.79

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후 EPS +2.3% 매출 +0.4%

🔔 Earnings release 2026년 2월 5일 (목) · 장 마감 후

Is it profitable?

Profitability healthy

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

27.5%

✓ 우수

My positionTop 5%

Low range Average High range

Diagnostics & Research 대형주 Median 18.9% · Top 3%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

21.4%

✓ 우수

My positionTop 25%

Low range Average High range

Diagnostics & Research 대형주 Median 11.9% · Top 6%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

57.3%

✓ 양호

My positionMid-range

Low range Average High range

Diagnostics & Research 대형주 Median 50.2% · Top 33%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROA

Annual earnings relative to total company assets

25.4%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 5.1% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

41.3%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 7.4% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Current Ratio

Liquid assets available to cover liabilities due within a year

1.20

✓ 평균

My positionMid-range

Low range Average High range

Diagnostics & Research Median 2.23

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.84

✓ 평균

My positionMid-range

Low range Average High range

Diagnostics & Research Median 2.15

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$1348.91

현재가 대비 +1.6%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

25.96배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

2.60

고평가

💡 PEG > 2 — 성장 대비 비싼 편

내년 EPS 예상 성장률

+9.6%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+10.0%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 2 of the last 2 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+3.3%

평균 서프라이즈

2026.05.07

상회

실적 $8.91 · 예상 $8.71 +2.3%

2026.02.05

상회

실적 $13.36 · 예상 $12.81 +4.3%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Concerns

Growth is lagging the industry average

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+9.2%

부진

My positionBottom 25%

Low range Average High range

성장주 대형주 Median 15.4% · Bottom 21%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+9.6%

부진

My positionBottom 25%

Low range Average High range

성장주 대형주 Median 13.1% · Bottom 21%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+10.0%

부진

My positionBottom 25%

Low range Average High range

성장주 대형주 Median 14.9% · Bottom 14%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+3.1%

평균

My positionMid-range

Low range Average High range

성장주 대형주 Median 9.2% · Bottom 36%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+11.0%

평균

My positionMid-range

Low range Average High range

성장주 대형주 Median 13.8% · Bottom 39%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+5.5%

부진

My positionBottom 25%

Low range Average High range

성장주 대형주 Median 10.3% · Bottom 20%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+7.2%

평균

My positionMid-range

Low range Average High range

성장주 대형주 Median 11.2% · Bottom 29%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -78%p below the market

MTD -10.2% · S&P 500 +68.0%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-78.1%p

Significantly behind the market

vs Health Care (XLV)

-33.8%p

Significantly behind the sector average

1-year basis

vs S&P 500

-11.2%p

behind the market

vs Health Care (XLV)

-14.5%p

behind the sector average

Rank among peers

5-year return Lower-Mid (lower 48%) Based on 15 peers

1-year return Lower-Mid (lower 27%) Based on 15 peers

Current position within 52-week range

Low (-29.7%p) High (-13.0%p)

Current price is 29.7% above the 52-week low and 13.0% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-26.8%

Annualized volatility

39.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-24

Uptrend zone

Current price $1327.18 above the midline ($1296.31). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-24

Neutral zone — weak trend

MACD 29.656 · Signal 31.422 · Hist -1.766. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-24

Bullish zone

RSI 60.9 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 85.3.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Earnings, In line with peers on Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🧾 Vs. Sales Mid-range

💧 Vs. Cash Flow Mid-range

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

31.13x

✓ Cheap

My positionMid-range

Low range Average High range

Diagnostics & Research median 35.22x · Around the industry average

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

25.96x

✓ Fair

My positionMid-range

Low range Average High range

Diagnostics & Research median 22.77x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

6.56x

✓ Fair

My positionMid-range

Low range Average High range

Diagnostics & Research 대형주 median 5.41x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

23.11x

✓ Fair

My positionMid-range

Low range Average High range

Diagnostics & Research median 22.23x · Around the industry average

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

33.78x

✓ Fair

My positionMid-range

Low range Average High range

Diagnostics & Research median 29.34x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$1348.91 vs. current price +1.6%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Diagnostics & Research

Who owns it?

Ownership flow shows some pressure

Insider modest net selling -0.5% · Institutional modest net selling -0.7% · Short interest light 3.7% · Short interest up +1.2pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-0.5%

Insiders net selling

🏦 Institutions (funds & investors)

-0.7%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 103.1%

Institution-led, stable structure

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 0.7%

Low, common among large-caps

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

3.7%

Low — limited short-side pressure

Healthcare 대형주 Median 3.6%

Past 90 days 📈 +1.2%p increase

Short interest days to cover

3.5 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 20.2M주

Float (tradable shares) 20.1M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding MTD

ETFs with the highest weightings · 10 total shown

MDEV

First Trust Indxx Medical Devices ETF

2.18%

$3M

UPGD

Invesco Bloomberg Analyst Rating Improvers ETF

1.88%

$117M

RSPH

Invesco S&P 500 Equal Weight Health Care ETF

1.85%

$740M

POWA

Invesco Bloomberg Pricing Power ETF

1.84%

$172M

NUMG

Nuveen ESG Mid-Cap Growth ETF

1.83%

$344M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
MTD This Stock	$26.8B	31.1 ▼	-	-	-	-0.3%
LLY	$1.13T	43.0 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.9%
JNJ	$634.1B	30.5 ▼	7.5 ▼	25.74% ▲	2.04% ▲	+1.6%
ABBV	$458.2B	127.9 ▼	-	15221.82% ▲	2.65% ▲	+0.9%
UNH	$382.1B	27.1 ▼	3.9 ▼	12.49% ▲	2.15% ▲	-0.7%
MRK	$323.7B	36.9 ▼	7.1 ▼	18.97% ▲	2.49% ▲	+0.5%
Sector Avg	-	25.8	2.7	-48.83%	1.25%	-

FAQ

What kind of company is 메틀러톨레도(MTD)?

메틀러톨레도(MTD) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is the market cap of MTD?

The market cap of MTD is approximately $26.8B, ranking 506 within its sector.

What is the P/E ratio of MTD?

MTD has a P/E ratio of approximately 31.1x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for MTD?

MTD has recorded a 52-week high of $1525.17 and a low of $1023.05.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.